2. Signaling Pathways
  3. TGF-beta/Smad
  4. TGF-β Receptor
  5. ALK4 Isoform

ALK4

ALK4, also known as activin receptor type-1B (ACVR1B), is a type I serine/threonine kinase receptor of the transforming growth factor-β (TGF-β) superfamily that functions as a key transducer of activin signaling[1][2]. Upon ligand engagement, activin first binds type II receptors, including ACVR2A or ACVR2B, which subsequently recruit and activate ALK4, leading to downstream phosphorylation of SMAD2 and SMAD3 and regulation of transcriptional programs involved in cell growth, differentiation, and homeostasis[1][2]. Mechanistically, ALK4 also mediates signaling induced by activin-like ligands and participates in canonical activin-SMAD signaling pathways that govern diverse physiological processes[1][2]. In experimental and disease-related contexts, genetic and functional studies have linked ACVR1B to tumor biology, including the identification of somatic ACVR1B mutations in pancreatic carcinoma, supporting a role for disrupted ALK4 signaling in cancer-associated pathways[3]. Compared with related type I receptors such as ALK5 (TGFBR1) and ALK7 (ACVR1C), ALK4 primarily functions as a receptor for activin-family ligands and therefore represents a distinct entry point into activin-dependent signaling networks[1][2]. For experimental applications, pharmacological blockade of ALK4 signaling is frequently achieved using SB-431542, a small-molecule inhibitor that targets ALK4 together with ALK5 and ALK7 and is widely used to interrogate activin/TGF-β pathway function in cellular models[4].

Cat. No. Product Name Effect Purity
  • HY-10431
    SB-431542
    		Inhibitor 99.85%
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways.
  • HY-10432
    A 83-01
    		Inhibitor 99.41%
    A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-10432A
    A 83-01 sodium
    		Inhibitor 98.03%
    A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
  • HY-10431G
    SB-431542 (GMP)
    		Inhibitor
    SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling.
  • HY-15897
    LDN-212854
    		Inhibitor 99.62%
    LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC).
  • HY-185430
    HM-279
    		Inhibitor
    HM-279 is a potent and orally active ALK5 inhibitor with an IC50 of 4.7 nM. HM-279 shows cross-reactivity with ALK7 (IC50 = 6.8 nM), but HM-279 has fair to good selectivity against other TGF-β receptor family kinases, with 4.5-693-fold selectivity. HM-279 demonstrates antitumor activity in vivo through CD8+ T cell immunity. HM-279 can be used for the research of colon cancer.
  • HY-117887
    Fidrisertib
    		Inhibitor 98.17%
    Fidrisertib (BLU-782) is the orally active inhibitor for activin receptor-like kinase 2 (ALK2) that inhibits ALK2R206H, ALK2, ALK1, ALK6, ALK3, ALK4, TGFβR2 and ALK5 with IC50s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively.
  • HY-122856
    AZ12601011
    		Inhibitor 99.78%
    AZ12601011 is an orally active, selective TGFBR1 kinase inhibitor with an IC50 of 18 nM and a Kd of 2.9 nM. AZ12601011 inhibits phosphorylation of SMAD2 via selectively inhibiting ALK4, TGFBR1, and ALK7. AZ12601011 inhibits mammary tumor growth .
  • HY-123900
    AZ12799734
    		Inhibitor 98.67%
    AZ12799734 is a selective, orally active TGFBR1 kinase inhibitor with an IC50 of 47 nM. AZ12799734 is also a pan BMP and TGFβ inhibitor.
  • HY-10432R
    A 83-01 (Standard)
    		Inhibitor
    A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC50s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively.
Cat. No. Product Name / Synonyms Species Source